ARHGAP15

Across TCGA pan-cancer cohorts, ARHGAP15 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGAP15 data layer compared with 20 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARHGAP15 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGAP15 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, COAD, and PDAC are the cancer types where ARHGAP15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.844	0.365	<.001	21	view →
COAD	DFS	Quartile	III,IV	0.730	1.000	.034	12	view →
PDAC	DFS	Median	All	0.888	0.711	.010	12	view →
HNSC	DFS	Median	II,III,IV	0.894	0.993	.004	10	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	4	view →
GBM	OS	Quartile	All	0.243	0.514	.020	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGAP15–LUAD (DFS)

Open the LUAD breakdown →